acepreoperative prediction of high-grade glioma (WHO III-IV) using integrative clinical-molecular Random Forest model
Source article: An integrative clinical-molecular model as an auxiliary predictive tool for glioma malignancy grade
Abstract: Objective An integrative auxiliary predictive model incorporating clinical parameters, serum biomarkers, and molecular pathological markers was developed to assess glioma malignancy grade. Methods This single-center retrospective observational study consecutively enrolled 400 glioma patients. A total of 26 variables, including demographic characteristics, clinical parameters, laboratory indicators, and serum biomarkers, were analyzed. Predictors were selected using univariate analysis, followed by Least Absolute…
Negative state: both sides are scored from claims and sources, not community votes.
"Hard metal lung disease/Giant cell interstitial pneumonia (GIP) - Case 259" by Pulmonary Pathology is licensed under CC BY-SA 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by-sa/2.0/.
On 2026-09-08, a peer-reviewed study reported development of an integrative clinical-molecular model for glioma malignancy grading using 400 patients from a single-center retrospective cohort. Using LASSO and machine learning, the authors built a Random Forest classifier based on seven predictors including age, KPS, tumor diameter, inflammatory ratios, IDH status and Ki-67, achieving AUC 0.864 in training and 0.820 in validation.
The result matters because accurate preoperative grading can inform surgical planning and individualized therapy, and the model showed good calibration and net benefit across threshold probabilities 0.2-0.8. Uncertainty remains because validation was internal only, the design was retrospective and single-center, and the model itself requires tissue-derived molecular markers, so it cannot substitute for standard pathological diagnosis.
- Single-center retrospective study of 400 glioma patients analyzed 26 clinical, laboratory and serum biomarker variables.
- LASSO regression and machine learning selected 7 independent predictors including age, KPS score, maximum tumor diameter, neutrophil-to-lymphocyte ratio, albumin-to-globulin ratio, IDH mutation status and Ki-67 index.
- Random Forest model showed excellent calibration with Hosmer-Lemeshow test p > 0.05 and clinical net benefit on decision curve analysis within 0.2-0.8 threshold probability range.
A Random Forest model integrating age, KPS, tumor diameter, NLR, AGR, IDH status and Ki-67 achieved AUC 0.864 training and 0.820 validation to assist preoperative assessment of high-grade glioma.
The auxiliary model cannot replace pathological and molecular diagnosis and relies on tissue-derived IDH and Ki-67 markers, with development limited to a single-center retrospective cohort of 400 patients and internal validation only.
The rundown
The study consecutively enrolled 400 glioma patients and evaluated 26 variables spanning demographics, clinical parameters, laboratory indicators and serum biomarkers. Univariate analysis followed by LASSO regression identified predictors, with SHAP analysis used for interpretability and AUC, calibration curves and decision curve analysis for performance.
Independent predictors for WHO grades III-IV included age OR 1.085, KPS OR 0.928, maximum tumor diameter OR 1.649, neutrophil-to-lymphocyte ratio OR 2.310, albumin-to-globulin ratio OR 0.163, IDH wild-type vs mutant OR 4.502, and Ki-67 OR 1.176. The authors position the model as an auxiliary preoperative tool that still requires tissue diagnosis.
Model is exploratory, single-center retrospective with internal validation only, and cannot replace pathological and molecular diagnosis because it depends on tissue-derived markers IDH and Ki-67.
Sources
- Peer-reviewedNeurological Research2026-09-08
How should this claim be treated?
The debate